Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
Targeted Oncology8d
FDA Clears IND for Phase 1 Trial of ADCE-T02 in Solid Tumors
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
Business Wire6d
SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
Our cutting-edge design overcomes these challenges, utilizing state-of-the-art linker-payload technology and an optimized antibody ... forward to filing an Investigational New Drug (IND ...